Genetron Holdings

Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the second quarter ended June 30, 2021 on Aug 24, 2021 before the US market open.

Genetron Health to Announce Second Quarter 2021 Financial Results and Host Investor Call on August 24, 2021

BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories' (“NCCL”) first nationwide, external quality assessment (“EQA”) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation “Outstanding Laboratory” and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation.

Genetron Health Tops NCCL's External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks

BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Province's Dafang County authorities to lead the “Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project”. Backed by the Central Committee of the Chinese Peasants and Workers Democratic Party and guided by China's National Cancer Center, this project is a collective effort that will be carried out by the Dafang County Health Bureau, the People's Hospital of Dafang, and Genetron Health.

Genetron Health Partners with Guizhou Province's Dafang County to Lead Liver Cancer Early Screening Project

BEIJING, July 26, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that its AYVAKIT® (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (“CStone”, HKEX: 2616) has entered the priority review and approval process under the National Medical Products Administration (NMPA) in China.

AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China

The CE Mark and comparative data highlight the Company's capability in providing high quality and consistent testing products The CE Mark and comparative data highlight the Company's capability in providing high quality and consistent testing products

Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform.

Genetron Health Enters into Platform Partnership with World Economic Forum

BEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Genetron Holdings announced earnings results on May 24 and the company saw strong revenue growth for the first quarter.

Genetron Holdings: Solid Revenue Growth Continues While Earnings Move Toward Profitability

Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2021 Results - Earnings Call Transcript

BEIJING, May 24, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the first quarter ended March 31, 2021.

Genetron Health Reports First Quarter 2021 Unaudited Financial Results

The stock price of Genetron Holdings Ltd (NASDAQ: GTH) increased by over 10% during intraday trading. This is why it happened.

Genetron Holdings (GTH) Stock: Over 10% Increase Explanation

BEIJING, May 20, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with JD Health, a subsidiary of JD.com, Inc., and the largest online healthcare platform in China. The two companies aim to create innovative solutions for full-cycle cancer management.

Genetron Health Announces Strategic Partnership with JD Health to Create Innovative Solutions for Full-cycle Cancer Management

Prometheus Biosciences

World Acceptance

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

3 Small Cap Stocks That Are Short Squeeze Candidates

SHANGHAI--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair. This partnership aims to promote large scale application of Genetron's S5 platform and lung cancer 8-gene IVD a

Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer

BEIJING, May 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2021 on May 24, 2021 before the US market open.

Genetron Health to Announce First Quarter 2021 Financial Results and Host Investor Call on May 24, 2021

BEIJING, April 22, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present and host one-on-one meetings at three upcoming investor conferences.

Genetron Health to Present at Upcoming Investor Conferences

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 22 research results at the American Association for Cancer Research Annual Meeting 2021 (AACR 2021). The results were from a series of studies that Genetron Health conducted with 13 leading hos

Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021

BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021.

Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH) sponsored a Science/AAAS Webinar, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”, which launched today. During the panel discussion, Genetron Health's Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled “Profiling cfDNA-based Biomarkers for the Early Detection of Cancer”. In his presentation, Dr. Jiao highlighted the impo

Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2020. 2020 Financial Highlights Recorded total revenue of RMB133.9 million (US$20.5 million) for the fo

Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Revenue Guidance

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today presented new data and results for HCCscreenTM, a blood-based early screening test for hepatocellular carcinoma (“HCC”). This multi-center prospective study, named the “HCCscreenTM Investigational Study” (HIT), is a co

Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar. 26th, 2021. Sizhen Wang, co-founder and Chief Executive Officer, will also attend a

Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the company will present at one of the Science/AAAS Webinar Series, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”. The webinar will be available o

Genetron Health to Present at Science/AAAS Webinar About Early Cancer Screening on March 31

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2020 on March 25, 2021 before the US market open. Management will host a conference call for in

Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its early liver cancer screening research results were cited by the "Chinese Anti-Cancer Association Guidelines for Patients with Primary Liver Cancer" (the "Guidelines"). The Guidelines, issued by the

News for Genetron Holdings Stock (GTH)